Coherus Biosciences, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Coherus Oncology announces its 2026 Annual Meeting of Stockholders, detailing proposals including director elections, auditor ratification, executive compensation advisory vote, stock option repricing, and equity plan expansion.
NASDAQ
DEFA14A: Coherus BioSciences Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote
Coherus BioSciences announces its 2025 Annual Meeting of Stockholders to be held on June 11, 2025, outlining key proposals for voting, including the election of directors, ratification of the auditor, executive compensation approval, and an amendment to the employee stock purchase plan.
NASDAQ
Coherus BioSciences is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the selection of its auditor, approve executive compensation, and amend its Employee Stock Purchase Plan.
NASDAQ
DEFA14A: Coherus BioSciences Addresses Stockholder Lawsuits with Additional UDENYCA Sale Disclosures
Coherus BioSciences provides supplemental disclosures regarding the proposed sale of its UDENYCA franchise to Intas Pharmaceuticals in response to stockholder demand letters and lawsuits.
NASDAQ
Coherus BioSciences plans to divest its UDENYCA franchise to Intas Pharmaceuticals for up to $558.4 million to strengthen its financial position and focus on its innovative oncology portfolio.
NASDAQ
Coherus BioSciences is set to sell its UDENYCA business to Intas Pharmaceuticals for $483.4 million in cash, plus potential earnout payments, as part of a strategic shift towards immuno-oncology.
NASDAQ
Coherus BioSciences details its strategic shift towards innovative oncology, highlighted by the UDENYCA franchise divestiture and advancements in its immuno-oncology pipeline.
NASDAQ
Coherus BioSciences is divesting its UDENYCA franchise to Intas Pharmaceuticals to strengthen its financial position and focus on its immuno-oncology pipeline.
NASDAQ
Coherus BioSciences is selling its UDENYCA franchise to Intas Pharmaceuticals for up to $558 million, allowing the company to focus on its immuno-oncology pipeline and reduce debt.
NASDAQ
Coherus BioSciences has agreed to sell its UDENYCA franchise to Intas Pharmaceuticals for up to $558 million, allowing the company to focus on its immuno-oncology portfolio and reduce debt.
NASDAQ
DEFA14A: Coherus BioSciences to Divest UDENYCA Franchise to Intas Pharmaceuticals for up to $558.4 Million
Coherus BioSciences will divest its UDENYCA franchise to Intas Pharmaceuticals for up to $558.4 million, allowing Coherus to focus on its immuno-oncology pipeline.
NASDAQ
Coherus BioSciences issues a supplement to its proxy statement clarifying details regarding the proposed amendment and restatement of its 2014 Equity Incentive Award Plan.
NASDAQ
Coherus BioSciences has scheduled its 2024 Annual Meeting for May 29, 2024, and is urging stockholders to vote on important proposals, including the election of directors, ratification of the company's accounting firm, an advisory vote on executive compensation, and approval of an amendment to the company's equity incentive plan.
NASDAQ
Coherus BioSciences is asking stockholders to approve an amended and restated 2014 Equity Incentive Award Plan at the upcoming annual meeting on May 29, 2024, including an increase in the share reserve and elimination of the evergreen provision.